Bayer-Perfuse Acquisition: PER-001 Endothelin Antagonist
Examine the Bayer-Perfuse acquisition and the clinical science of PER-001, a novel endothelin receptor antagonist for glaucoma and diabetic retinopathy.
Back to Articles
Articles tagged with “bayer-perfuse-acquisition”